Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk
Acta Haematologica · 2022 · 145 (2) · 221-228
DOI: 10.1159/000520438 ↗Kurz gefasst
Fallbericht in der Zeitschrift Acta Haematologica, online erschienen am 14.12.2021. Verfasst von Amit R Mehta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Premier Hematology and Tele-Oncology Center, PLLC, Cary, North Carolina, USA. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia, Thrombosis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Patients with immune thrombocytopenia (ITP) are at increased risk for bleeding and are paradoxically at increased risk for thrombosis. Many patients with ITP have underlying cardiovascular (CV) disease and/or other thrombotic risk factors for which considerable attention to selecting a therapeutic agent to manage ITP is needed. Fostamatinib, a spleen tyrosine kinase inhibitor, may reduce the risk of thrombosis while not interfering with hemostasis. We present a case series of 5 patients with ITP who had significant CV histories; each had at least 2 thrombotic risk factors. After unsuccessful management of ITP with other treatments, fostamatinib was initiated, was observed to be tolerable, and provided a durable platelet response without associated thromboembolic events. Fostamatinib may be the treatment of choice for patients with ITP in whom use of prothrombotic treatments should be avoided and/or continued use of antiplatelet or anticoagulant medication is needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Premier Hematology and Tele-Oncology Center, PLLC, Cary, North Carolina, USA.
- Duke Regional Hospital, Durham, North Carolina, USA.
- Northwest Georgia Oncology Centers, Athens, Georgia, USA.
- OptumCare Cancer Care, Las Vegas, Nevada, USA.
- AMITA Health Medical Group, Chicago, Illinois, USA.
- Northwestern University, Chicago, Illinois, USA.
Zitieren
APA
Mehta, A. R., Kefela, A., Toste, C., & Sweet, D. (2022). Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk. Acta Haematologica, 145(2), 221-228. https://doi.org/10.1159/000520438
Vancouver
Mehta AR, Kefela A, Toste C, Sweet D. Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk. Acta Haematologica. 2022;145(2):221-228. doi:10.1159/000520438
BibTeX
@article{Mehta2022,
author = {Mehta, Amit R and Kefela, Aron and Toste, Charina and Sweet, Donald},
title = {Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk},
journal = {Acta Haematologica},
year = {2022},
volume = {145},
number = {2},
pages = {221--228},
doi = {10.1159/000520438}
}
EUVIMED